April 11, 2025

New Self-Injection Option for gMG, CIDP

A prefilled syringe version of VYVGART Hytrulo, which enables adult patients with generalized myasthenia gravis or chronic inflammatory demyelinating polyneuropathy to self-administer treatment in as little as 20 to 30 seconds, has been approved by the FDA.

Conexiant

April 11, 2025

FDA Clears Longest Lasting CGM

Dexcom G7 15 Day receives FDA clearance, offering adults with diabetes the longest lasting and most accurate continuous glucose monitoring system to date.

Conexiant

April 10, 2025

FDA to Pilot Animal-Free Models

"This initiative marks a paradigm shift in drug evaluation and holds promise to accelerate cures and meaningful treatments for Americans while reducing animal use."

Reuters

April 10, 2025

Palmoplantar Keratoderma with Hearing Loss: What's Your Diagnosis?

Rare case of Vohwinkel syndrome highlights the importance of recognizing characteristic clinical features in diagnosing hereditary palmoplantar keratodermas with systemic manifestations.

Conexiant

April 09, 2025

Dual Immunotherapy Approved for Advanced CRC

The FDA approved nivolumab with ipilimumab for unresectable or metastatic microsatellite instability–high or mismatch repair–deficient colorectal cancer.

Conexiant

April 08, 2025

Study Identifies Biologic Reasons for Selective Benefit of PARP Inhibitors

In the journal Nature, Lahiri et al shared a possible biologic explanation for why some patients with cancer may benefit from PARP inhibitors, and others may not. They used specialized imaging tools t...

The ASCO Post

April 07, 2025

HHS FOIA Staff Cuts Slow Data

Thousands of pending FOIA requests are likely to be affected.

KFF Health News

April 04, 2025

First IgG4-RD Treatment Approved

A humanized monoclonal antibody that targets CD19+ B cells is first FDA-approved treatment for immunoglobulin G4–related disease, reducing flare risk and glucocorticoid use in clinical trials.

Conexiant

April 03, 2025

New Option for IgA Nephropathy Management

The FDA has granted accelerated approval to Vanrafia (atrasentan) for reducing proteinuria in adults with primary immunoglobulin A nephropathy who are at risk of rapid disease progression.

Conexiant